LifeSci Advisors

@LifeSciAdvisors

Investor Relations, Capital Markets Advisory, Corporate Communications, Non-Deal Roadshows, and Social Media.

New York, NY
Vrijeme pridruživanja: travanj 2011.

Tweetovi

Blokirali ste korisnika/cu @LifeSciAdvisors

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @LifeSciAdvisors

  1. Inventiva Full-Year 2019: Cash position and revenues

    Poništi
  2. Phio Pharmaceuticals Announces $1.74 Million Registered Direct Offering Priced At-the-Market

    Poništi
  3. Acerus Announces Acceptance of Two NATESTO® Clinical Studies for Presentation at the American Urological Association Annual Scientific Program

    Poništi
  4. Oncocyte Closes Merger Agreement to Acquire Insight Genetics

    Poništi
  5. HTG Molecular Diagnostics : EdgeSeq miRNA Whole Transcriptome Assay is Highly Reproducible in Biofluids for Potential Use as a Biomarker

    Poništi
  6. Salarius Pharmaceuticals to Present at the BIO CEO & Investor Conference

    Poništi
  7. Announces Third Quarter Fiscal 2020 Financial and Operating Results

    Poništi
  8. Emmaus Life Sciences Reports Preliminary Gross Sales for the Three Months Ended December 31, 2019

    Poništi
  9. CytoSorbents : CytoSorb Used Successfully to Help Treat Grade 4 Cytokine Release Syndrome Following CAR T-cell Immunotherapy in First Published Case Report

    Poništi
  10. Trevena to Present at the 2020 BIO CEO & Investor Conference

    Poništi
  11. Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2019 Financial Results and Host Conference Call on February 12, 2020

    Poništi
  12. 4. velj

    Genkyotex Announces Its Financial Calendar For 2020

    Poništi
  13. 4. velj

    Protalix BioTherapeutics to Participate in the 2020 BIO CEO & Investor Conference and the Noble Capital Markets' 16th Annual Small & Microcap Investor Conference

    Poništi
  14. 4. velj

    Outlook Therapeutics to Present at the 2020 BIO CEO & Investor Conference

    Poništi
  15. 4. velj

    Immutep to Present TACTI-002 Interim Data at German Cancer Congress

    Poništi
  16. 4. velj

    Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors

    Poništi
  17. 4. velj

    Altimmune to Present at Upcoming Investor and Scientific Conferences

    Poništi
  18. 4. velj

    Compugen Announces New U.S. Patent for Methods of Screening for Anti-PVRIG Antibodies

    Poništi
  19. 3. velj

    Inventiva selected to present the positive results from its Phase IIa clinical study with odiparcil in MPS VI at the 16th Annual WORLDSymposium

    Poništi
  20. 3. velj

    CorMedix Announces FDA Grant of Rolling Review of Neutrolin® New Drug Application

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·